---
title: "MK-677 (Ibutamoren)"
slug: "mk-677"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/mk-677"
description: "An oral growth hormone secretagogue (Ibutamoren) that raises GH and IGF-1 without injections. Clinical pharmacology, appetite effects, and protocol notes."
---
# MK-677 (Ibutamoren)

*Non-Peptide Growth Hormone Secretagogue, Amplifying Endogenous GH and IGF-1 Output*

**Category:** Body Composition  
**Format:** Lyophilized Vial  
**Amount:** 25mg  
**Purity:** >99% (HPLC)

## Overview

MK-677, also known as Ibutamoren or Ibutamoren Mesylate, is a potent, orally active, non-peptide growth hormone secretagogue developed by Merck Research Laboratories in the mid-1990s. Unlike traditional growth hormone-releasing peptides (GHRPs) that require injection, MK-677 is a small molecule compound with the molecular formula C27H36N4O5S and a molecular weight of 528.66 g/mol. It functions as a selective agonist of the growth hormone secretagogue receptor (GHSR), also known as the ghrelin receptor, mimicking the endogenous hormone ghrelin to stimulate pulsatile growth hormone release from the anterior pituitary gland.

MK-677 is not a peptide, hormone, or steroid. It is classified as a non-peptide spiropiperidine compound, a small molecule that was designed to replicate the growth hormone-releasing activity of peptide secretagogues while offering the significant advantage of oral bioavailability. This distinction is critical for understanding its pharmacological profile, as MK-677 achieves growth hormone elevation through a physiological mechanism that preserves the natural pulsatile pattern of GH secretion, unlike exogenous growth hormone administration which delivers continuous, non-physiological hormone levels.

The mechanism of action of MK-677 centers on its high-affinity binding to the GHSR-1a receptor, the same receptor that binds the endogenous peptide hormone ghrelin. When MK-677 engages the GHSR-1a receptor on somatotroph cells in the anterior pituitary, it triggers a signaling cascade involving phospholipase C (PLC) activation, inositol trisphosphate (IP3) generation, and subsequent calcium release from intracellular stores. This calcium influx stimulates the exocytosis of growth hormone-containing secretory granules, releasing GH into the bloodstream in a pulsatile fashion that mirrors natural physiology.

Beyond direct pituitary stimulation, MK-677 amplifies growth hormone release through a secondary hypothalamic mechanism. It stimulates growth hormone-releasing hormone (GHRH) neurons in the arcuate nucleus while simultaneously suppressing somatostatin signaling, the primary inhibitory regulator of GH secretion. This dual action at both the hypothalamic and pituitary levels produces a more robust and sustained elevation of growth hormone than either mechanism alone. Clinical studies published in the Journal of Clinical Endocrinology and Metabolism have demonstrated that MK-677 administration produces dose-dependent increases in both GH pulse amplitude and IGF-1 levels.

One of the most significant pharmacological properties of MK-677 is its prolonged duration of action. Unlike injectable GHRP compounds that produce acute, short-lived GH pulses, a single oral dose of MK-677 sustains elevated GH secretion for up to 24 hours. This extended activity is attributed to the compound's long plasma half-life of approximately 4-6 hours and the sustained nature of GHSR activation. Research has shown that daily MK-677 administration leads to consistent elevation of mean 24-hour GH concentrations and a significant increase in circulating IGF-1 levels, typically reaching a new steady state within 2-4 weeks of continuous dosing.

The effects of MK-677 on the GH/IGF-1 axis have been extensively characterized in multiple clinical trials involving healthy volunteers, elderly subjects, and individuals with relative GH deficiency. In a landmark study published in the Annals of Internal Medicine, two months of MK-677 treatment in healthy older adults increased GH secretion to levels comparable to those observed in young adults, with concurrent increases in IGF-1 and IGFBP-3 levels. Body composition analysis revealed increases in fat-free mass and a trend toward reduced abdominal visceral fat.

MK-677 also influences several other physiological systems beyond the GH/IGF-1 axis. Its ghrelin-mimetic activity affects appetite regulation, as ghrelin is known as the hunger hormone. Research subjects consistently report increased appetite during MK-677 administration, a predictable effect of GHSR activation in hypothalamic feeding centers. The compound has also been shown to improve sleep quality, with studies demonstrating increased duration of stage IV (deep) sleep and REM sleep, likely mediated through GH-dependent mechanisms given the established relationship between growth hormone secretion and sleep architecture.

The metabolic effects of MK-677 extend to bone mineral density, where long-term studies have demonstrated positive effects on markers of bone turnover. Research published in the Journal of Clinical Endocrinology and Metabolism showed that 12 months of MK-677 administration increased markers of bone formation, including osteocalcin and bone-specific alkaline phosphatase, suggesting potential utility in research related to age-related bone loss. Additionally, MK-677 has been studied for its effects on nitrogen balance, with data suggesting it can reverse diet-induced catabolism by promoting nitrogen retention through GH-mediated anabolic pathways.

It is important to note that MK-677 does not suppress the hypothalamic-pituitary-gonadal axis and does not affect cortisol, prolactin, or thyroid hormone levels at standard research dosages. However, it does modestly increase fasting glucose and insulin levels due to GH-mediated hepatic glucose output, a consideration that is relevant for individuals with impaired glucose tolerance or insulin resistance. This metabolic effect mirrors the well-characterized diabetogenic properties of growth hormone itself and requires monitoring in research settings.

## Mechanism of Action

### Step 1: GHSR-1a Receptor Binding

MK-677 binds with high affinity to the growth hormone secretagogue receptor (GHSR-1a) on pituitary somatotroph cells, mimicking the endogenous ligand ghrelin and initiating intracellular signaling through phospholipase C activation.

### Step 2: Calcium-Mediated GH Exocytosis

GHSR-1a activation triggers IP3-mediated calcium release from intracellular stores, driving the exocytosis of growth hormone-containing secretory granules and producing pulsatile GH release that mirrors natural secretory patterns.

### Step 3: Hypothalamic GHRH/Somatostatin Modulation

MK-677 simultaneously stimulates GHRH neurons in the arcuate nucleus while suppressing somatostatin release, removing the inhibitory brake on GH secretion and amplifying the pituitary response to produce more robust GH output.

### Step 4: Sustained IGF-1 Elevation

Elevated GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which mediates many of the anabolic, tissue-repair, and metabolic effects attributed to GH. IGF-1 levels rise steadily over 2-4 weeks of daily administration.

### Step 5: Anabolic and Metabolic Downstream Effects

Sustained GH and IGF-1 elevation promotes nitrogen retention, lipolysis, lean tissue accretion, bone mineral turnover, and improvements in sleep architecture through GH-dependent modulation of deep sleep stages.

## Researched Benefits

### Sustained Growth Hormone Elevation

Clinical trials demonstrate that MK-677 produces consistent, dose-dependent increases in 24-hour GH secretion and IGF-1 levels. In elderly subjects, it restored GH profiles to levels observed in young adults. The oral route and long duration of action distinguish it from injectable GH-releasing peptides that produce only short-lived GH pulses.

### Improved Body Composition

Research in healthy older adults showed that MK-677 increased fat-free mass and trended toward reduced visceral adiposity over 2-month treatment periods. These effects are mediated through GH-stimulated lipolysis and IGF-1-driven nitrogen retention, promoting a favorable shift in the ratio of lean mass to fat mass.

### Enhanced Sleep Quality

Studies have documented increased duration of stage IV (deep) sleep and REM sleep during MK-677 administration. Given the established role of growth hormone in sleep architecture, this effect likely reflects the compound's physiological amplification of GH pulsatility during nocturnal secretory peaks.

### Bone Metabolism Support

Long-term research (12 months) demonstrated that MK-677 increased markers of bone formation including osteocalcin and bone-specific alkaline phosphatase. These findings suggest positive effects on bone turnover balance, which is relevant for research into age-related changes in skeletal integrity.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 10-25mg per day, administered orally once daily, typically in the evening |
| Route | Oral administration |
| Duration | 8-12 week cycles, with some research protocols extending to 12 months |
| Cycle Notes | Many protocols use 25mg daily for 8-12 weeks. Evening dosing is often preferred to align with natural nocturnal GH peaks and to mitigate daytime appetite stimulation. Some protocols incorporate dose titration starting at 10mg. |
| Reconstitution | For research-grade lyophilized formulations, reconstitute with bacteriostatic water per standard protocols. MK-677 is also commonly available in oral capsule or solution forms for research applications. |

> **Specialist note:** A your specialist will evaluate fasting glucose, insulin sensitivity, and metabolic markers before initiating MK-677. Individuals with diabetes, pre-diabetes, or impaired glucose tolerance require careful monitoring due to GH-mediated effects on hepatic glucose output. Concurrent insulin-sensitizing agents may be incorporated into some protocols.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 25mg per vial |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Composition | Ibutamoren Mesylate (MK-677), spiropiperidine non-peptide compound |
| Molecular Weight | 528.66 g/mol |
| Storage | Store at room temperature (15-25°C) in a dry, light-protected environment. Reconstituted solutions at 2-8°C. |
| Appearance | White to off-white powder |

## Medical Guidance

MK-677 activates the GH/IGF-1 axis and produces ghrelin-mimetic metabolic effects, including increased appetite and elevated fasting glucose. Individuals with diabetes, insulin resistance, metabolic syndrome, or a history of pituitary disorders require thorough medical assessment. MK-677 is contraindicated in individuals with active malignancies due to the growth-promoting properties of IGF-1. Cardiovascular risk factors should also be evaluated given the metabolic implications of sustained GH elevation.

## Frequently Asked Questions

### What is MK-677 and is it a peptide?

MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue. It is a small molecule compound classified as a spiropiperidine that mimics the action of ghrelin, the endogenous hunger hormone. Unlike GH-releasing peptides such as GHRP-6 or Ipamorelin that require injection, MK-677 is effective when taken orally and produces sustained GH elevation over a 24-hour period.

### How does MK-677 differ from exogenous growth hormone?

MK-677 stimulates the body's own pituitary gland to produce and release growth hormone in a natural pulsatile pattern, whereas exogenous GH delivers a continuous, non-physiological dose. MK-677 preserves the feedback mechanisms of the GH axis and does not cause pituitary suppression. It also offers oral dosing convenience compared to the daily injections required for exogenous GH.

### Does MK-677 affect testosterone or other hormones?

Research data indicate that MK-677 does not suppress the hypothalamic-pituitary-gonadal axis and does not affect testosterone, cortisol, prolactin, or thyroid hormone levels at standard dosages. It selectively targets the GH/IGF-1 axis through the ghrelin receptor. However, it does modestly increase fasting glucose and insulin levels, which requires metabolic monitoring.

### Why is MK-677 typically dosed in the evening?

Evening dosing is often preferred because growth hormone secretion naturally peaks during early sleep stages, particularly during stage IV deep sleep. Aligning MK-677 administration with this nocturnal GH peak amplifies the physiological secretory pattern. Evening dosing also helps minimize the impact of increased daytime appetite, a predictable effect of ghrelin receptor activation.

### What metabolic monitoring is recommended during MK-677 research?

Because MK-677 can increase fasting glucose and insulin levels through GH-mediated hepatic glucose output, monitoring of fasting blood glucose, HbA1c, and insulin levels is recommended. IGF-1 levels should be tracked to confirm GH axis activation and ensure levels remain within appropriate ranges. Baseline and periodic metabolic panels are standard in research protocols.

## Related Compounds

- /compounds/cjc-1295-ipamorelin
- /compounds/tesamorelin
- /compounds/aod-9604